DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Phase 2

Completed

Conditions: Bladder Cancer
Muscle-invasive Bladder Cancer

Interventions: Drug: Methotrexate
Drug: Doxorubicin
Drug: vinblastine
Drug: cisplatin
Drug: Pegfilgrastim

First Posted Date: 2008-12-16

Last Posted Date: 2016-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00808639

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 1 locations

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1

Completed

Conditions: Neuroendocrine Tumor
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor

Interventions: Drug: SOM230
Drug: RAD001

First Posted Date: 2008-12-08

Last Posted Date: 2016-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00804336

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Pilot Study of Acupuncture Treatment for Dysphagia

Not Applicable

Completed

Conditions: Dysphagia
Carcinomas, Squamous Cell

Interventions: Device: Acupuncture

First Posted Date: 2008-11-25

Last Posted Date: 2018-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT00797732

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Bevacizumab Plus Ipilimumab Cohort 2
Drug: Bevacizumab Plus Ipilimumab Cohort 4
Drug: Bevacizumab Plus Ipilimumab Cohort 1
Drug: Bevacizumab Plus Ipilimumab Cohort 3

First Posted Date: 2008-11-13

Last Posted Date: 2023-05-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00790010

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Phase 2

Completed

Conditions: Mucosal Lentiginous Melanoma
Acral Melanoma
Melanoma

Interventions: Drug: Nilotinib

First Posted Date: 2008-11-11

Last Posted Date: 2018-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00788775

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
The Angeles Clinic and Research Institute, Santa Monica, California, United States

and more 5 locations

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Phase 2

Completed

Conditions: Glioma
Low-grade Glioma
Astrocytoma

Interventions: Drug: everolimus

First Posted Date: 2008-10-31

Last Posted Date: 2018-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00782626

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Memorial Sloan-Kettering Cancer Institute, New York, New York, United States

and more 7 locations

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Androgen Deprivation Therapy
Drug: bicalutamide
Drug: bevacizumab

First Posted Date: 2008-10-21

Last Posted Date: 2016-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 102

Registration Number: NCT00776594

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 5 locations

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Sunitinib

First Posted Date: 2008-10-07

Last Posted Date: 2018-08-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT00768144

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States

Personal Patient Profile Prostate (P4) Randomized, Multisite Trial

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: P4

First Posted Date: 2008-06-06

Last Posted Date: 2015-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 498

Registration Number: NCT00692653

Locations: 🇺🇸
VA Medical Center / Medical College of Georgia, Augusta, Georgia, United States
🇺🇸
Seattle Prostate Institute, Seattle, Washington, United States
🇺🇸
Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States

and more 3 locations

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: T Cell Non-Hodgkin Lymphoma

Interventions: Drug: Imatinib mesylate

First Posted Date: 2008-05-26

Last Posted Date: 2017-01-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00684411

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy